Justice Served: CVS Caremark Hit With $290 Million Penalty for Defrauding Medicare Taxpayers

(Substack)—A whistleblower’s courage has led to a major victory against corporate overreach in the bloated Medicare system. Federal Judge Mitchell Goldberg, appointed by President George W. Bush, has slapped CVS Health’s pharmacy benefit manager, Caremark, with a nearly $290 million bill for scheming to overcharge Medicare on prescription drugs back in 2013 and 2014.

This ruling underscores the rampant fraud plaguing government entitlement programs, where hardworking Americans’ tax dollars are siphoned off by big players exploiting the system.

The case stems from allegations by Sarah Behnke, a former Aetna actuary who blew the whistle on Caremark’s manipulative practices. Behnke claimed the company defrauded Medicare Part D by submitting false drug cost reports, effectively hiding profits and overbilling the program by $95 million.

After a non-jury trial in March, Caremark was found liable in June, with damages initially set at $95 million. Judge Goldberg then tripled that amount and tacked on $4.87 million in civil penalties, bringing the total to $289.9 million. He cited reckless disregard and deliberate ignorance on Caremark’s part, though not outright knowledge of the fraud.

Court documents reveal how Caremark allegedly orchestrated the scheme by prompting Aetna and SilverScript to file false direct and indirect remuneration reports. This not only padded their pockets but also burdened taxpayers with inflated costs in an already overburdened Medicare framework. To add insult to injury, post-judgment interest is now accruing on the full amount until Caremark pays up, ensuring the company can’t drag its feet without consequences.

CVS isn’t taking this lying down. “We are pleased that the Behnke ruling in June was in our favor as to certain issues for CVS Pharmacy and CVS Health Corporation’s liability and disappointed the court found against Caremark on other issues. We plan to appeal,” the company stated.

This isn’t an isolated incident—it’s symptomatic of deeper issues in federal healthcare programs. Medicare fraud alone drains an estimated $60 billion from the system each year, representing a staggering loss of taxpayer funds that could otherwise support genuine needs or reduce the national debt. Improper payments across Medicare and Medicaid have ballooned, with recent estimates pegging total waste, fraud, and abuse at up to 30% of healthcare spending in some analyses. The Trump administration highlighted $140 billion in improper payments for 2024 alone, a figure that exposes the inefficiencies of government-run healthcare.

Conservatives have long warned about the vulnerabilities in these expansive programs, where lack of oversight invites abuse from corporations and providers alike. While free enterprise drives innovation, entanglements with federal bureaucracies often breed corruption, as seen here with one of the nation’s largest pharmacy chains. Behnke’s role as a whistleblower under the False Claims Act highlights the importance of individual accountability in exposing such schemes, but it also begs the question: Why does it take private citizens to police a system funded by public dollars?

As the national debt spirals beyond $37 trillion, cases like this reinforce the need for bold reforms—slashing wasteful spending, imposing stricter audits, and perhaps rethinking the government’s oversized role in healthcare.

President Trump’s past efforts to root out fraud through enhanced program integrity measures showed promise, recovering billions, but more must be done to protect taxpayers from these predatory practices. Until then, victories like this $290 million judgment serve as a reminder that justice can prevail, even in the face of big pharma’s influence.